NCT02718443View on ClinicalTrials.gov

VXM01 Phase I Pilot Study in Patients With Operable Recurrence of a Glioblastoma

PHASE1CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

May 31, 2016

Primary Completion Date

August 31, 2017

Study Completion Date

July 31, 2018

Conditions
Glioblastoma
Interventions
DRUG

VXM01

Oral immunotherapy targeting VEGFR2

Trial Locations (1)

69120

Neurology Clinic and National Center for Tumor Diseases, Heidelberg

All Listed Sponsors
lead

Vaximm GmbH

INDUSTRY

NCT02718443 - VXM01 Phase I Pilot Study in Patients With Operable Recurrence of a Glioblastoma | Biotech Hunter | Biotech Hunter